Numeral studies with mTOR inhibitors (i.e. everolimus, temsirolimus, deforolimus) showpromise in the ER-positive and/or HER2-positive breast cancer (Fasolo & Sessa 2008, Vicieret al. 2014, Baselgaet al. 2017). Here, ERBB2 is linked to breast carcinoma.